Olink Platform

Targeted Proteomics

Within the framework of the TheraNova Innovation Center, a scalable platform for protein quantification has been established, enabling the identification of protein biomarkers in various biological samples such as blood, urine, or tissue fluids. Biomarkers are used for example in clinical diagnostics and as indicators for treatment selection and monitoring of disease progression. Furthermore, they contribute to a better understanding of underlying disease mechanisms.

Protein quantification is performed using Proximity Extension Assay (PEA) technology from Olink Proteomics (Olink Homepage). Various products are available that enable the quantification of both a small number of proteins (>5) and a larger number of biomarkers (>1,000 proteins) with high specificity and sensitivity. Only very small sample volumes are required to perform the experiments, which is particularly relevant for rare and low-volume samples. In addition to individual sample measurements, high-throughput projects can also be carried out.

Further information on our technology plattforms (ITMP Homepage)

Tabbed contents

Expand all Close all

Applications and Services

Preclinical and clinical studies

Identification of diagnostic, prognostic and predictive biomarkers
Identification of surrogate markers for efficacy and safety
Patient stratification

Research projects

Biomarker analyses in different in vitro-, ex vivo and in vivo model systems
Validation studies
Mechanistic analyses

Services offered

Analysis of single samples up to big cohorts (high-throughput analyses) in longitudinal studies
Preparation of protocols for sample collection and preanalytical sample processing
Project/study support from preparation to data processing

Selected Publications

1: Saul D, Lischer C, Bruns H, Ziegler N, Kannt A, Michel M, Mougiakakos D. OGG1 activation improves T cell resilience to oxidative stress after allo-SCT and T cell engager exposure. Leukemia. 2025 Dec;39(12):3037-3041. doi: 10.1038/s41375-025-02783-4. Epub 2025 Oct 15.PMID: 41094011.

2: Remih K, Hufnagel FM, Karl AS, Durkalski-Mauldin V, Lee WM, Karvellas CJ, Su Z, Rule JA, Tomanová P, Krieg L, Karkossa I, Schubert K, von Bergen M, Tacke F, Luckhardt S, Ziegler N, Kannt A, Engel B, Taubert R, Fontana RJ, Strnad P; US Acute Liver Failure Study Group. Serum proteomics of adults with acute liver failure provides mechanistic insights and attractive prognostic biomarkers. JHEP Rep. 2025 Jan 30;7(5):101338. doi: 10.1016/j.jhepr.2025.101338. PMID: 40242314; PMCID: PMC11998117.

3: Rischke S, Gurke R, Zielbauer AS, Ziegler N, Hahnefeld L, Köhm M, Kannt A, Vehreschild MJ, Geisslinger G, Rohde G, Bellinghausen C, Behrens F, Study Group C. Proteomic, metabolomic and lipidomic profiles in community acquired pneumonia for differentiating viral and bacterial infections. Sci Rep. 2025 Jan 14;15(1):1922. doi: 10.1038/s41598-025-85229-2. PMID: 39809876; PMCID: PMC11733231.

4: Youhanna S, Kemas AM, Wright SC, Zhong Y, Klumpp B, Klein K, Motso A, Michel M, Ziegler N, Shang M, Sabatier P, Kannt A, Sheng H, Oliva-Vilarnau N, Büttner FA, Seashore-Ludlow B, Schreiner J, Windbergs M, Cornillet M, Björkström NK, Hülsmeier AJ, Hornemann T, Olsen JV, Wang Y, Gramignoli R, Sundström M, Lauschke VM. Chemogenomic Screening in a Patient-Derived 3D Fatty Liver Disease Model Reveals the CHRM1-TRPM8 Axis as a Novel Module for Targeted Intervention. Adv Sci (Weinh). 2025 Jan;12(3):e2407572. doi: 10.1002/advs.202407572. Epub 2024 Nov 28. PMID: 39605182; PMCID: PMC11744578.

5: Roser LA, Luckhardt S, Ziegler N, Thomas D, Wagner PV, Damm G, Scheffschick A, Hewitt P, Parnham MJ, Schiffmann S. Immuno-inflammatory in vitro hepatotoxicity models to assess side effects of biologicals exemplified by aldesleukin. Front Immunol. 2023 Nov 17;14:1275368. doi: 10.3389/fimmu.2023.1275368. PMID: 38045689; PMCID: PMC10693457.